OPKO Health (OPK) Q1 2026 earnings summary

Executive summary

• Advanced ModeX pipeline with five clinical programs in vaccines, oncology, and immunology, including first-in-human trials for MDX2301 (COVID prevention) and MDX2003 (B-cell lymphoma), with promising early data presented at major conferences.

• Strategic partnerships with Merck, Regeneron, BARDA, and Entera Bio provide non-dilutive capital, milestone opportunities exceeding $1 billion, and expanded programs such as a daily long-acting PTH tablet targeting an IND filing in late 2026.

• Diagnostics business streamlined post-oncology divestiture, focusing on core labs and specialty testing, with improved operational efficiency and profitability targets.

• Completed sale of oncology diagnostics business to Labcorp for $192.5 million in 2025, with eligibility for up to $32.5 million in contingent consideration.

• Stock repurchase program increased to $200 million, with $92 million spent as of March 31, 2026, and $108 million remaining authorized.

Financial highlights

• Q1 2026 total revenue was $124.2 million, down from $149.9 million in Q1 2025, mainly due to the oncology divestiture and lower clinical test volumes.

• Diagnostics revenue was $72.2 million (including $6.5 million from 4Kscore); pharmaceutical revenue was $52 million, with product revenue up 9% to $38 million and IP/other revenue up 14% to $14 million.

• Gross margin improved to $45.8 million from $42.6 million year-over-year, driven by higher volume and efficiency.

• Consolidated operating loss improved to $51 million from $67.2 million year-over-year; net loss was $54.8 million ($0.07/share), better than $67.6 million ($0.10/share) in Q1 2025.

• Cash, cash equivalents, and restricted cash totaled $355.6 million at quarter-end.

Outlook and guidance

• Q2 2026 revenue expected between $127 million-$132 million; full-year 2026 revenue guidance: $530 million-$560 million.

• Service revenue guidance for Q2: $72 million-$76 million; pharmaceutical product revenue: $38 million-$42 million; IP and other revenue: $15 million-$19 million, including Pfizer profit share of $6 million-$8 million.

• R&D spending expected at $32 million-$38 million for Q2 and $125 million-$135 million for the full year, offset by $5 million-$7 million in BARDA funding.

• Management expects to file an IND for the LA-PTH program with the FDA in late 2026.

• Affirmed full-year guidance; current cash resources sufficient for operational and debt service needs beyond the next 12 months.